PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.44%
EBIT growth 10-15% – Solid. Seth Klarman would see if this level of profit expansion is sustainable across cycles.
14.44%
Operating income growth 10-15% – Solid. Seth Klarman would look at whether overhead costs remain controlled for long-term stability.
12.51%
Net income growth 10-15% – Solid. Seth Klarman would verify if cost control or pricing is driving consistent profit expansions.
12.37%
EPS growth 10-15% – Solid. Seth Klarman would see if share dilution or buybacks significantly affected the results.
12.37%
Diluted EPS growth 10-15% – Solid. Seth Klarman would check if share-based compensation is offsetting part of net income gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.24%
OCF growth 0-5% – Minimal gain. Howard Marks would be cautious about the company’s ability to fund large projects or dividends.
1.24%
FCF growth 0-5% – Slight improvement. Howard Marks would be cautious about cyclical or temporary factors limiting free cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.48%
A negative 10Y OCF/share CAGR signals erosion in long-term cash generation. Benjamin Graham would label this as a major red flag.
-6.48%
A negative 5Y OCF/share CAGR indicates declining cash generation per share mid-term. Benjamin Graham would see this as a red flag unless explained by short-term strategic investments.
-6.48%
Negative 3Y OCF/share CAGR shows recent erosion in operating cash. Benjamin Graham would see this as a cautionary signal unless explained by strategic investments.
-180.68%
A negative 10Y net income/share CAGR reflects a decade of weakening profits. Benjamin Graham would be extremely cautious unless a turnaround is evident.
-180.68%
A negative 5Y net income/share CAGR reveals a mid-term deterioration in bottom-line earnings. Benjamin Graham would be cautious unless a credible turnaround is visible.
-180.68%
Negative 3Y net income/share CAGR highlights recent bottom-line decay. Benjamin Graham would want clarity on cost vs. revenue drivers for the declines.
-183.69%
Negative 10Y equity/share CAGR indicates a long-term decline in book value. Benjamin Graham would be extremely cautious about net worth destruction.
-183.69%
Negative 5Y equity/share CAGR suggests net worth destruction. Benjamin Graham would see if failing profitability or large payouts cause it.
-183.69%
Negative 3Y equity/share CAGR means a near-term drop in book value. Benjamin Graham would be cautious unless restructured operations promise a future rebound.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.05%
Negative asset growth may reflect divestitures or depreciation outpacing new investments. Benjamin Graham wonders if shedding non-core assets improves focus or signals trouble.
-17.69%
Falling book value/share indicates net losses, large dividends, or intangible impairments. Benjamin Graham warns unless there’s a strategic reason.
7.69%
Debt up 5-10% yoy – Noticeable leverage. Howard Marks questions if the returns outstrip higher interest costs.
No Data
No Data available this quarter, please select a different quarter.
175.10%
SG&A growth above 15% – Aggressive expense expansion. Philip Fisher demands a compelling ROI argument for such heavy spending.